Scilex forms JV to develop Phase 2 oral KDS2010 for obesity and Alzheimer's

Scilex Holding Co

Scilex contributes $50M of Semnur stock for controlling stake in Scilex Bio JV; IPMC holds 40%.
NeuroBiogen grants Scilex Bio exclusive worldwide license to KDS2010 for all indications.
KDS2010 is a reversible MAO-B inhibitor; Phase 1 shows favorable safety; Phase 2 ongoing in obesity and Alzheimer's.
Obesity drug market forecast ~$150B by early 2030s; Alzheimer's market >$15B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.